微生物疗法的机遇与挑战（观点）

[IF:11.743]

Microbial therapeutics: New opportunities for drug delivery

微生物疗法：药物递送的新机会

10.1084/jem.20190609

04-26, Editorial Material

Abstract & Authors:展开

Abstract:收起
With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.

First Authors:
Miguel Jimenez

Correspondence Authors:
Robert Langer,Giovanni Traverso

All Authors:
Miguel Jimenez,Robert Langer,Giovanni Traverso

本站仅提供存储服务，所有内容均由用户发布，如发现有害或侵权内容，请点击举报。